Program

download as PDF

07:00 PM - 10:00 PM 3h

07:00 PM - 10:00 PM

Welcome reception
07:45 PM - 08:15 PM

Opening Keynote Lecture

Immune function in patients with CLL

A P Kater
08:15 PM - 10:00 PM

Working Dinner

Looks like there are no sessions today for the selected program.

09:30 AM - 11:00 AM 1h 30min

Young Investigator Meeting (YIM)

P Langerbeins, L Ysebaert

YIM Session I: Clinical & Translational Research

09:30 AM - 09:45 AM

Selected YIM-Abstract #1

Ibrutinib lead-in followed by venetoclax plus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia

I Romano
09:45 AM - 10:00 AM

Selected YIM-Abstract #2

Incidence of Richter transformation in patients with chronic lymphocytic leukemia (CLL): a cohort study evaluating different therapeutic eras

P J Hampel
10:00 AM - 10:15 AM

Selected YIM-Abstract #3

Prevalence and clinical impact of clonal hematopoiesis in chronic lymphocytic leukemia

R Moia
10:15 AM - 10:30 AM

Selected YIM-Abstract #4

Preclinical efficacy of the BCL2i venetoclax combined with MEKi cobimetinib or SYKi entospletinib in BTKi-refractory CLL patients harboring BTK mutations

S Martindale
10:30 AM - 10:45 AM

Selected YIM-Abstract #5

Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia

I Ashworth
10:45 AM - 11:00 AM

Selected YIM-Abstract #6

The Gene Expression Landscape of BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia Exposed by Shallow Depth RNA Sequencing

T H L Do

11:30 AM - 01:00 PM 1h 30min

Young Investigator Meeting (YIM)

M Hallek, D Stephens

YIM Session II: Translational & Basic Research

11:30 AM - 11:45 AM

Selected YIM-Abstract #7

TLR9 signaling is a potential tumor escape mechanism following B-cell receptor targeted treatments in subsets of

E Kennedy
11:45 AM - 12:00 PM

Selected YIM-Abstract #8

BH3 Profiling Identifies Anti-Apoptotic Dependencies and Therapeutic Vulnerabilities in Primary Richter Transformation (RT) Cells and in a Genetically-Engineered Murine Model of RT

N Javidi-Sharifi
12:00 PM - 12:15 PM

Selected YIM-Abstract #9

LYN kinase activity and its regulator CSK are key players in CLL supporting macrophages

V Kohlhas
12:15 PM - 12:30 PM

Selected YIM-Abstract #10

Impact of Germline and Somatic ATM Variants in Chronic Lymphocytic Leukemia (CLL): Clinical Implications and Response to PARP Inhibition

K Mashima
12:30 PM - 12:45 PM

Selected YIM-Abstract #11

Role of G protein-coupled receptor kinase 2 (GRK2) in the localization and activation of leukemic cells

C Cassarino
12:45 PM - 01:00 PM

Selected YIM-Abstract #12

Rps15-S138F mutation results in translational errors underlying onset of chronic lymphocytic leukemia

N Ruthen

01:45 PM - 02:05 PM 20min

German CLL Study Group studies

K Fischer, P Staber

01:45 PM - 01:55 PM

CLL 13 - Minimal Residual Disease: status and outcome

M Ritgen
01:55 PM - 02:05 PM

CLL12 | CLL13 | CLL14 - Genetic subgroups: different studies, same findings?

E Tausch

02:05 PM - 02:30 PM 25min

German CLL Study Group studies

K Fischer, P Staber

02:05 PM - 02:10 PM

CLL ReVenG

M Davids
02:10 PM - 02:15 PM

CLL16

N Kutsch
02:15 PM - 02:20 PM

CLL17

O Al-Sawaf
02:20 PM - 02:30 PM

Discussion

Plenum

02:30 PM - 02:50 PM 20min

German CLL Study Group studies

K Fischer, P Staber

02:30 PM - 02:35 PM

CLLRT1

B Eichhorst
02:35 PM - 02:40 PM

CLLFrail

F Simon
02:40 PM - 02:50 PM

Discussion

Plenum

02:50 PM - 03:20 PM 30min

German CLL Study Group studies

K Fischer, P Staber

02:50 PM - 02:55 PM

CLL18

P Cramer
02:55 PM - 03:00 PM

CLLRT2

S Stilgenbauer
03:00 PM - 03:05 PM

Shall we address the tumor microenvironment?

A vom Stein
03:05 PM - 03:10 PM

Bendamustine debulking - yes or no?

J v Tresckow
03:10 PM - 03:20 PM

Discussion

Plenum

03:50 PM - 04:50 PM 1h

Session I

R Guièze , C Herling

03:50 PM - 04:05 PM

Genomic Map of CLL

BA Knisbacher
04:05 PM - 04:20 PM

Richter Transformation

F Nadeu
04:20 PM - 04:35 PM

TP53 and beyond

P Robbe
04:35 PM - 04:50 PM

Genetic and epigenetic evolution

R Rosenquist

04:50 PM - 05:50 PM 1h

Young Investigator Meeting (YIM)

P Langerbeins, D Stephens, L Ysebaert

YIM Session III: Guided Poster Walk with Coffee & Tea

04:50 PM - 05:00 PM

Selected Abstract #13 (Poster)

Adaptation of chronic lymphocytic leukemia to ibrutinib is L mediated by epigenetic plasticity of residual disease and by-pass signaling via MAPK pathway

L Terzi di Bergamo
05:00 PM - 05:10 PM

Selected Abstract #14 (Poster)

Combined therapy of endocytosis inhibitors and a novel glycoengineered anti-ROR1 antibody to enhance antibody-dependent cellular cytotoxicity (ADCC) against chronic lymphocytic leukemi

K Hasan
05:10 PM - 05:20 PM

Selected Abstract #15 (Poster)

A Comparative Study of Different Macrophage Feeder Systems for the Support of Chronic Lymphocytic Leukemia Survival

H Jestrabek
05:20 PM - 05:30 PM

Selected Abstract #16 (Poster)

CAR T cells generated from CLL patients are characterized by determinants of immune dysfunction that may be positively modulated by treatment with targeted agents

F Perutelli
05:30 PM - 05:40 PM

Selected Abstract #17 (Poster)

Venetoclax resistant cells are sensitive to anti-CD20 V monoclonal antibodies.

V J Sarapura Martinez
05:40 PM - 05:50 PM

Selected Abstract #18 (Poster)

Utility of the international chronic lymphocytic leukemia prognostic index in front-line treatment with targeted drugs

S Robrecht

05:50 PM - 06:20 PM 30min

Satellite Symposium

AbbVie

05:50 PM - 06:20 PM

Time limited treatment regimens in CLL – Present or Future

S Stilgenbauer

06:20 PM - 06:50 PM 30min

Satellite Symposium

C Herling

AstraZeneca

06:20 PM - 06:50 PM

Pattern of Resistance in CLL and its Clinical Implications

O Al-Sawaf

07:40 PM - 08:20 PM 40min

Keynote Lecture

07:40 PM - 07:50 PM

Introduction

M Hallek
07:40 PM - 08:20 PM

Keynote Lecture

J Woyach

Looks like there are no sessions today for the selected program.

09:15 AM - 10:00 AM 45min

Session II

L Scarfò, M Davids

Treatment of CLL

09:15 AM - 09:30 AM

Selecting a first-line treatment – what do we know, what do we need, what is standard?

T Munir
09:30 AM - 09:45 AM

Relapsed CLL – is it just second first-line?

P Thompson
09:45 AM - 10:00 AM

Double Refractory (BTKi and BCL2i:) – what comes next?

M Hallek

10:00 AM - 10:30 AM 30min

Satellite Symposium

BeiGene

10:00 AM - 10:30 AM

"Mental health in patients with CLL"

L Fallowfield, C M Wendtner

11:00 AM - 11:30 AM 30min

Satellite Symposium

M Trepel

Janssen

11:00 AM - 11:30 AM

"CLL therapy today and tomorrow"

M Trepel, P Ghia

11:30 AM - 12:15 PM 45min

Session III

T Kipps, P Thornton

Daily challenges in CLL management

11:30 AM - 11:45 AM

Autoimmune conditions

M Coscia
11:45 AM - 12:00 PM

Infections

L Scarfò
12:00 PM - 12:15 PM

Richter Transformation

R Guièze

01:30 PM - 02:00 PM 30min

Satellite Symposium

Lilly

01:30 PM - 02:00 PM

"Latest CLL data – ready for clinical routine?"

J v Tresckow, H Huber

02:00 PM - 03:00 PM 1h

Session IV

D Rossi, J Brown

Perspectives

02:00 PM - 02:15 PM

Novel targets

A Danilov
02:15 PM - 02:30 PM

Cellular and bispecific therapies

F Bosch
02:30 PM - 02:45 PM

Prognostic & predictive factors: future roles

I Ahn
02:45 PM - 03:00 PM

Dream your study

S Parikh

Looks like there are no sessions today for the selected program.

Day 1

04/18/2024

Day 2

04/19/2024

Day 3

04/20/2024